| Autor: |
Diamantopoulos, P.T. Athanasiadou, A. Papakostas, E. Gratsias, N. Georgiou, G. Mantzourani, M. Andreopoulos, G. Panagiotidis, P. Aessopos, A. Meletis, J. Viniou, N. |
| Jazyk: |
angličtina |
| Rok vydání: |
2011 |
| Předmět: |
|
| Popis: |
The category of myelodysplastic syndromes/myeloproliferative diseases (MDS/MPD) is a relatively new group of malignant hematologic diseases developed by the World Health Organization. These hematologic disorders lack the BCR/ABL fusion gene, although they can be associated with chromosomal translocations that involve genes encoding other protein kinases. Imatinib mesylate was recognized as a potent inhibitor of some of those kinases. We present a patient with a previously treated acute myeloid leukemia, who, after a 9-year-long remission, developed an MDS/MPD with normal karyotype, which initially responded to imatinib mesylate. Translocation t(12;13)(p12;q14) was detected after loss of response to imatinib treatment. Translocation t(12;13) is rare. It has been described in several hematologic malignancies including chronic myelomonocytic leukemia but not in MDS/MPD, previously described as Philadelphia-negative chronic myelogenous leukemia. Moreover, the correlation of this molecular abnormality with loss of efficacy of imatinib is unique in the literature. © 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
